Uncategorized

FDA approves new treatment Galafold (migalastat) for a rare genetic disorder, Fabry disease — New Drug Approvals

FDA approves new treatment for a rare genetic disorder, Fabry disease The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. The drug is indicated for adults with Fabry disease who have a genetic mutation determined to be responsive (“amenable”) to treatment with […]

via FDA approves new treatment Galafold (migalastat) for a rare genetic disorder, Fabry disease — New Drug Approvals

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s